Abstract
An integrated interface was designed to connect the platform in Chap. 2 and the module in Chap. 3 together forming a fully integrated system for automated genetic analysis. The chips and the instrument were also upgraded correspondingly. The upgraded integrated chip is a compound material one that uses plastic chip for sample preparation and glass chip for capillary electrophoresis detection. The cheap plastic chip is disposable while the glass chip is reusable after cleaned up after each run. A special shaped sample electrode for electrophoresis was designed as the core component of the integrated interface. The specific designed sample electrode was verified to be able to mix the PCR products with the premixed, and transport the mixture from PMMA chip onto glass chip. With this interface, a new fully integrated “sample-in-answer-out” genetic analysis system was constructed. The integrated system was verified on reliability and repeatability. And the limit of detection was also determined. The system was applied for rapid pharmacogenetic typing of multiple warfarin-related single-nucleotide polymorphisms and the test results met the design requirements.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rubin EH, Allen JD, Nowak JA, Bates SE. Developing precision medicine in a global world. Clin Cancer Res. 2014;20(6):1419–27.
Mooney SD. Progress towards the integration of pharmacogenomics in practice. Hum Genet. 2015;134(5):459–65.
Ashley EA. The precision medicine initiative a new national effort. JAMA. 2015;313(21):2119–20.
Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet. 2012;379(9827):1705–11.
Katsnelson A. Momentum grows to make ‘personalized’ medicine more ‘precise’. Nat Med. 2013;19(3):249.
Flockhart DA, O’Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008;10(2):139–50.
Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015;25(1):33–41.
Daniel SB, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. New Engl J Med. 2011;365(21):2002–12.
Lee MTM, Klein TE. Pharmacogenetics of warfarin: challenges and opportunities. J Hum Genet. 2013;58(6):334–8.
Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90(4):625–9.
Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009;150(2):73–U31.
Epstein RS, Moyer TP, Aubert RE, O’Kane DJ, Xia F, Verbrugge RR, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study). J Am Coll Cardiol. 2010;55(25):2804–12.
Poe BL, Haverstick DM, Landers JP. Warfarin genotyping in a single pcr reaction for microchip electrophoresis. Clin Chem. 2012;58(4):725–31.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Zhuang, B. (2018). Fully Integrated Genetic Analysis System. In: Development of a Fully Integrated “Sample-In-Answer-Out” System for Automatic Genetic Analysis. Springer Theses. Springer, Singapore. https://doi.org/10.1007/978-981-10-4753-4_4
Download citation
DOI: https://doi.org/10.1007/978-981-10-4753-4_4
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-4752-7
Online ISBN: 978-981-10-4753-4
eBook Packages: EngineeringEngineering (R0)